Therapeutic management of ischemic stroke

Area of Science:

• Neurology
• Cardiovascular Medicine
• Regenerative Medicine

Background:

• Stroke is a major global cause of mortality and disability.
• Ischemic stroke (artery occlusion) and hemorrhagic stroke (brain bleeding) are the primary types.
• Alteplase is the sole FDA-approved thrombolysis therapy for ischemic stroke.

Purpose of the Study:

• To review current understanding and clinical research on stroke diagnosis, assessment, and management.
• To explore past, present, and future therapeutic strategies for stroke.
• To focus on stroke pathogenesis, recent advancements, and potential therapeutic targets.

Main Methods:

• Literature search of PubMed and Google Scholar for therapeutic regimes.
• Review of clinical research and current views on stroke management.
• Analysis of advancements in endovascular therapy and intravenous thrombolysis.

Main Results:

• Therapeutic options for ischemic stroke have significantly expanded since 1995 and 2015.
• Novel approaches like vagus nerve stimulation show potential for significant patient benefit.
• Therapeutic hypothermia is a potent neuroprotectant with established clinical and preclinical efficacy.

Conclusions:

• Rapid intervention in stroke is linked to improved clinical outcomes.
• Future stroke therapy may involve innovative approaches beyond traditional methods.
• Understanding stroke pathogenesis is crucial for developing effective therapeutic targets.